Microdose GLP-1: Compounding Rules and Shortage Context

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub — evidence-based GLP-1, metabolic, and genetics education. Explore the full library any time.

"Microdose GLP-1" refers to lower-dose compounded formulations of the active ingredient, produced by licensed 503A compounding pharmacies rather than FDA-approved brand manufacturers. To understand where these fit, it helps to look at what compounding pharmacies can legally do, what recent FDA shortage decisions changed, and how compounded products actually compare to brands.

What a 503A pharmacy can legally do

503A pharmacies are state-licensed compounders that prepare patient-specific prescriptions under a valid prescriber order. Federal law lets them compound in three broad situations: products not commercially available, products on the FDA drug shortage list, and patient-specific formulations — a different strength, combination, or vehicle — that are medically necessary for an individual. State pharmacy boards and the FDA maintain oversight.

What the 2024–2025 shortage resolutions changed

The FDA declared semaglutide in shortage in 2022 and tirzepatide in shortage in 2022. During those declarations, 503A pharmacies could compound the molecules under the shortage pathway. The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, which narrowed — but did not close — the legitimate compounding window. Compounded semaglutide and tirzepatide remain available through the not-commercially-available and patient-specific pathways where clinically justified.

How compounded compares to brand products

Compounded products are legally and factually different from FDA-approved brand products. They are not subject to the same FDA manufacturing review, follow their own pharmacy-specific quality processes, and may use different vehicles, strengths, or combinations. Quality varies by pharmacy, so verifying state licensure and, where possible, third-party testing matters. Importantly, compounded products are not "generics" in any regulatory sense.

Where microdose and combination formulations fit

Semaglutide combined with cyanocobalamin (vitamin B12) is a common variation; the B12 can reduce injection-site irritation for some patients and may support energy and neurological health in those who are B12-deficient. "Microdose" formulations deliver lower doses than standard titration schedules, sometimes for patients who experience significant GI effects at label-directed doses. Specific strength combinations are patient-specific per the prescriber order. PlexusDx offers a Microdose GLP-1 Protocol within its Weight Management Protocols.

Safety considerations and the genetic layer

Confirm the compounding pharmacy is licensed in your state and that a prescribing provider performs a clinical evaluation and reviews contraindications. Be wary of vendors that ship without prescriptions, accept only cryptocurrency, or market "research chemical" products. Alongside those checks, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, and MC4R that shape baseline GLP-1 and energy-balance biology. It provides pathway context, never a prediction of drug response. See What Is GLP-1.

Questions worth asking a compounding pharmacy

Because compounded products fall outside the FDA manufacturing review that branded drugs undergo, a little diligence protects you. The most basic question is whether the pharmacy is licensed in your state, since 503A compounding operates under state pharmacy board oversight. From there, it is reasonable to ask about the pharmacy's quality processes and whether third-party testing is available for the formulations it prepares.

Signals worth noticing

Legitimate compounded products arrive with patient-specific labeling, lot numbers, beyond-use dates, and storage instructions consistent with USP standards, and they follow a valid prescriber order after a clinical evaluation. Vendors that skip the prescription step, insist on cryptocurrency, or market "research chemical" material are operating outside that framework and are worth avoiding. A provider who evaluates your history and reviews contraindications is part of the same safeguard. Microdose and combination formulations can be reasonable, patient-specific options in the right hands, but the value depends entirely on the legitimacy of the pharmacy and the oversight behind the prescription rather than on the label attached to the product. A few honest questions upfront tell you far more about what you are getting than any marketing claim, and a reputable pharmacy will answer them without hesitation.

Frequently Asked Questions About Microdose GLP-1

What does microdose GLP-1 mean?

Microdose formulations deliver lower doses than standard titration schedules, produced as patient-specific prescriptions by licensed 503A compounding pharmacies. They are sometimes used for patients who experience significant GI effects at label-directed doses. The specific strength is set per the prescriber order rather than a fixed commercial dose.

Can pharmacies still compound semaglutide after the shortage ended?

Yes, in narrower circumstances. The FDA resolved the semaglutide shortage in late 2024 and tirzepatide in early 2025, but the not-commercially-available and patient-specific compounding pathways remain open where clinically justified. Compounding under the shortage pathway specifically ended when each shortage was resolved.

Is a compounded product the same as a generic?

No. Compounded products are legally and factually different from FDA-approved brands and are not generics in any regulatory sense. They follow pharmacy-specific quality processes rather than the FDA manufacturing review that brands undergo, so verifying state licensure and third-party testing is worthwhile.

How does genetics relate to a microdose approach?

The Precision Peptide Genetic Test does not predict response or set a dose. It analyzes variants such as FTO and MC4R, and TCF7L2 that shape baseline appetite and energy-balance biology, giving your provider pathway-level context that applies across GLP-1 decisions, including compounded formulations.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.